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Abstract
Hepatitis C affects approximately 180 million people worldwide, with 3–4 million newly 
infected each year. Hepatitis C virus (HCV) has been classified into seven different genotype 
categories, wherein HCV genotype 1 (HCV-1) is the most prevalent. To date, there is still no 
vaccine available against HCV infection. Until recently, combination therapy of pegylated 
interferon-a (PegIFN) and ribavirin (RBV) has been the standard of care. Nevertheless, for 
many patients, particularly those infected with HCV genotype 1 (HCV-1), this treatment 
has resulted with unsatisfactory treatment response rates and high adverse drug reaction 
(ADR) rates. Many clinical factors, including pharmacogenetics, influence the treatment 
response rate. This review focuses on the association between pharmacogenetics and HCV 
antiviral therapy in patients infected with HCV genotype 1 and other genotypes (GT); 
patients reinfected with HCV after liver transplantation; and patients coinfected with HCV 
and human immunodeficiency virus. Data considering triple therapy in HCV-infected 
patients are also reviewed. Additionally, various genetic polymorphisms, with an empha-
sis to IL-28B, and their association with pharmacogenetic testing in HCV are discussed.
Keywords: hepatitis C virus, pharmacogenetics, pegylated interferon and ribavirin, 
direct-acting antiviral agents, genetic polymorphisms, IL-28B, ITPA
1. Introduction
1.1. Clinical background of HCV infection
Infection with hepatitis C virus (HCV), an enveloped single-stranded RNA virus of the 
Flaviviridae family, affects over 2% of the worldwide population and it is estimated that 
the number of people with a chronic HCV infection is over 180 million, representing an 
© 2017 The Author(s). Licensee InTech. Distributed under the terms of the Creative Commons Attribut on-
NonCommercial 4.0 License (https://creativecommons.org/l censes/b -nc/4 0/), which permits use, distribution
and reproduction for non-commercial purposes, provided the original is properly cited.
important public health issue [1, 2]. Epidemiological studies have shown that 46.2% of all 
hepatitis C cases are caused by HCV GT1, making GT1 the most prevalent genotype [3]. 
Even though most of the patients initially do not experience any symptoms, about 75% are 
not able to spontaneously clear the virus from the organism, and develop a chronic HCV 
infection [4]. HCV causes progressive liver injury in those patients, which in approxi-
mately 16% progress to liver cirrhosis and ultimately in 1–5%, within two decades from 
acute infection, to hepatocellular carcinoma. Therefore, HCV infection is one of the most 
common reasons for liver failure and an indication for liver transplantation procedures 
worldwide [5–7]. HCV has been classified into seven different genotype categories, hav-
ing nucleotide differences of greater than 30% among genotypes (GT). Due to that fact, 
the task to produce pan-genotypic drugs has been very demanding [8]. Accordingly, the 
response of HCV infection to treatment regimens and its duration can vary depending on 
viral genotype [9].
1.2. Changes in the HCV treatment goals and HCV treatment timeline development
The search for optimal hepatitis C treatment has been ongoing even before the HCV had 
been cloned in 1989 [10, 11]. The ultimate goal of every standard-of-care treatment from that 
point in history was the cure of hepatitis C, in particular, the removal of the virus from the 
organism and prevention of further liver damage due to HCV. A patient is considered to be 
cured when sustained virological response (SVR) is reached, defined as undetectable HCV 
RNA viral load 24 or 12 weeks post-therapy [12, 13]. Formerly, SVR had been determined 
6 months (24 weeks) after completion of treatment with interferon-cased therapy. However, 
with direct-acting agents, that are so much more potent, it has been shown that the viral clear-
ance can be assessed 12 weeks after therapy. Thus, SVR12 is the currently advised standard 
[14, 15]. At the time when interferon (IFN)-α was approved as the first anti-HCV drug in the 
SVR, it was only achieved in 2–7% of treated patients [16]. The addition of ribavirin (RBV) 
and the later change of IFN-α to its pegylated form (PegIFN (pegylated interferon-a)) in the 
therapeutic regimen increased the SVR marginally. Even though the dual therapy containing 
PegIFN-RBV showed to be a considerably effective treatment for patients who were infected 
with HCV GT2 or GT3, achieving SVR in up to 80% of the treated patients, the success in cur-
ing patients infected with HCV GT1 was still izbaciti R skroz below 50% despite treatment 
prolongation up to 72 weeks [17, 18]. Also, many treated patients suffered from severe and 
potentially life threatening adverse drug reactions (ADRs) such as influenza-like syndrome, 
anemia, leukopenia, thrombocytopenia, depression, concentration issues, gastrointestinal 
ADRs, etc., which often led to preterm therapy dismissal [19]. Consequently, there was a 
great need to develop novel targeted drugs, with higher efficacy and fewer ADRs. In order 
to develop such drugs, scientific progress in the fields of virology, molecular biology, and 
biochemistry and an understanding of the individual steps in the HCV replication cycle had 
to be determined. This led to the discovery of contributing viral proteins such as NS3/4A pro-
tease, NS5A polymerase, and NS5B replication complex as possible therapeutic targets [20]. 
The development of ciluprevir (Biln 2061), the first NS3 protease inhibitor (PI), in 2002 was 
the first attempt to develop direct-acting antivirals (DAA) and influence the HCV replication 
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cycle (Figure 1). Even though ciluprevir was found to perform rapid antiviral activity, the 
clinical trials had to be discontinued due to cardiac toxicity and this drug was never approved 
for use [21–23]. Telaprevir (TLV) and boceprevir (BOC) were approved in combination with 
PegIFN and ribavirin (RBV) for the treatment of HCV GT1 infections by the FDA in May 
2011. These were the first DAAs to reach the market [24–26]. Whereas, the so-called triple 
therapy, containing one of the two NS3/4A inhibitors TLV or BOC with PegIFN and RBV, 
markedly increased the number of patients with HCV GT1 infections achieving SVR in >70%, 
severe ADRs often led to discontinuation of therapy [27–29]. Indeed, since the triple therapy 
also involved PegIFN and RBV, some adverse effects induced by those drugs were persistent 
compared with the previous treatment regimen. However, the addition of NS3/4A protease 
inhibitor (PI) not only intensified some of the IFN-induced ADRs such as anemia, but also 
led to novel side effects like skin rashes, gastrointestinal disorders and dysgeusia [18, 30]. In 
November 2013, simeprevir (SMV), as a second generation NS3/4A inhibitor was approved 
by the FDA, which contrary to prior developed drugs in this class, was more convenient 
regarding dosing and had fewer ADRs [31, 32]. Subsequently, the first HCV NS5B polymerase 
inhibitor sofosbuvir (SOF) was approved. The combination of SOF with PegIFN and RBV 
shortened the treatment to 12 weeks and achieved SVR in 90% of the treated patients [33]. 
Figure 1. Timeline of discoveries in the history of HCV and the dynamics of SVR through time depending on the 
standard-of-care treatment. SVR rates did improve greatly since 1991, when IFN-α got approved as the first drug for 
patients with hepatitis C. Nowadays, the therapy with DAAs made chronic hepatitis C a curable disease with SVR rates 
over 93%.
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Finally, in 2014, a great step forward was made regarding pharmacotherapy of HCV-infected 
patients by the approval of first all-oral IFN-free regimens. The first IFN-free regimens, 
3D-combination dasabuvir (DSV) plus ombitasvir (OBV) plus paritaprevir/ritonavir (PTV/r) 
+/− RBV (whereby OBV has been the first approved drug in the class of NS5A inhibitors), as 
well as ledipasvir (LDV) plus sofosbuvir (SOF were marketed in 2014 [34, 35]. Moreover, in 
July 2015, daclatasvir (DCL) and the fixed combination of OBV plus paritaprevir plus rito-
navir became FDA approved, followed by elbasvir plus grazoprevir as well as velpatasvir 
plus sofosbuvir in 2016 [36–39]. Presently, as a result of IFN-free DAA treatment regimens, 
92–100% of treatment naïve patients infected with HCV GT1 achieve SVR [40]. Provided that 
with IFN-free treatments shortage of therapy duration, improvements in efficacy and fewer 
ADRs are possible, the prospect of HCV eradication became a real opportunity rather than 
an unachievable goal [41]. However, the extremely high costs of IFN-free regimens combined 
with limited healthcare resources hinder accessibility of this valuable therapy worldwide.
2. Pharmacogenetic testing
During the past decades, much effort has been applied toward improvement of the safety and 
efficiency of drugs used for the treatment of many diseases, including hepatitis C. Adverse 
drug reactions (ADRs) are a significant cause of morbidity and mortality in patients. However, 
existing evidence considering individualization of pharmacotherapeutic regimens based on 
the patient genetic information indicate that ADRs could be at least partially overcome by 
the application of pharmacogenetics and pharmacogenomics. Pharmacogenetics is a scientific 
field for studying differences in drug response and the occurrence of adverse drug reactions 
due to the genetic impact of variations in individual genes, whereas pharmacogenomics stud-
ies the impact of the whole genome on drug response, nowadays using genome-wide associa-
tion studies (GWAS) as successful tools [42–44].
Pharmacogenomics is a rapidly emerging and promising scientific field, used to improve 
drug safety by avoiding specific drugs to susceptible individuals who are likely to develop 
ADRs [45]. Although there are still challenges remaining, with the improvement of study 
designs and the establishment of international cooperation pharmacogenomic study results 
could be validated and pharmacogenetic testing could become a clinical reality [45, 46]. 
Additional studies with even more participants are likely to yield results in the near future, 
which could enhance the number of clinical implementations of pharmacogenetic test results 
and make another step toward personalized medicine [46]. The cost-effectiveness of drugs is 
likely to improve by the implementation of pharmacogenomic tests, since the drugs should 
be used only to treat patients expected to experience a satisfactory therapeutic effect, with 
minimal risk for morbidity and mortality [47–50]. Furthermore, it is of enormous significance 
to educate clinicians on data interpretation of pharmacogenetic test results, so that they could 
gain the required knowledge to accurately stratify patients into high risk or low risk groups 
regarding drug toxicity. Consequently, therapeutic outcome would be improved without put-
ting susceptible patients at risk of predictable life threatening ADRs. Therefore, new user-
friendly and up-to-date guidelines should be made for clinicians, which could help the future 
implementation of pharmacogenomic study results into the clinical daily routine [45, 51–53].
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3. HCV pharmacogenetic testing in the IFN era
As previously mentioned, combination of PegIFN and RBV had been the standard-of-care for 
patients with chronic hepatitis C for more than a decade [9]. Notwithstanding, many patients 
still did not respond to therapy and could not achieve SVR or developed adverse events [54]. 
It has been noticed that many clinical factors, including pharmacogenetics, could influence 
the treatment response rate [9]. Both virological factors (such as HCV genotype, quasispecies 
diversity, and baseline viremia) and host factors (age, gender, race-ethnicity, fibrosis stage, 
obesity, hepatic steatosis, low-density lipoprotein cholesterol, insulin resistance, and genetic 
variances) played an important role in predicting the natural course of hepatitis C and IFN 
response to therapy [7, 55–57]. Pharmacogenetic testing could play very important role in 
optimizing HCV therapy by identifying variations in response to treatment, considering eth-
nic variations in response to therapy, enlightening the molecular mechanism of current and 
future therapies, and advancement of innovative genetic tools that will enable physicians to 
individualize drug therapy, adjust dosages, and reduce the possibility of adverse drug reac-
tions and therapeutic costs (Table 1) [54, 58]. Over 40 genes have been linked to modulation 
of anti-HCV therapy affecting either adverse drug events or response to treatment [59, 60].
Genetic 
polymorphism
Mechanism of action Favorable 
genotypes
Use in predicting 
treatment outcomes
Use in predicting 
adverse drug 
events
IL28B rs8099917
IL28B rs12979860
Triggers JAK-STAT pathway 
and activates ISG
rs8099917 TT
rs12979860 CC
HCV 1, HCV 4 infection, 
liver transplantation, 
HIV-HCV coinfection
NO
ITPA rs1127354
ITPA rs7270101
Reduced ITPA activity 
advances the accumulation of 
ITP in erythrocytes, reduces 
ATP depletion and protects 
against hemolytic anemia 
caused by RBV
rs1127354 AA/AC
rs7270101 CC/CA
NO HCV 1 infection, 
HIV-HCV 
coinfection
G protein b3 unit 
(GNB3) C825T
Transmits signals via the G 
protein-coupled receptors, 
consequently advancing 
immune response
rs5443 TT HIV-HCV coinfection NO
LDLR rs14158 Decreases HCV entry into 
hepatocytes
rs14158 CC
rs12979860 CC
HCV-1 infection, HIV-
HCV coinfection
NO
CTLA4 A49G Decreases suppression of 
T-cell proliferation, adjusts the 
threshold of T-cell activation
rs231775 GG HCV-1 infection, HIV-
HCV coinfection
NO
IL 6* C174G Involved in liver regeneration 
and in protection against 
hepatic injury
rs1800795 GG HCV-1 infection, HIV-
HCV coinfection
NO
Abbreviations: IL28B, interleukin 28B; ITPA, inosinetriphosphatase; LDLR, low-density lipoprotein receptor; CTLA, 
cytotoxic lymphocyte antigen 4; IL 6, interleukin 6.
Note: Data for IL28B from Kamal [54], for ITPA, G protein b3 unit, LDLR, CTLA4 and for IL 6 from Kawaguchi-Suzuki 
and Fyre [9].
Table 1. Most important host genetic polymorphisms associated with HCV pharmacogenetic testing in the IFN era.
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3.1. IL 28B polymorphisms in prediction of HCV infection treatment outcome
IL 28B gene belongs to the type III IFN family named IFN-λ located on the human chromo-
some 19, and corresponds to IFN-λ3 [7]. Viral infection induces the corresponding cytokines 
and their antiviral activity is mediated by triggering JAK–STAT pathway [61–63]. ISGs (inter-
feron stimulated genes), which are known to cause apoptosis, growth inhibition, and inhibi-
tion of viral replication, are activated by JAK–STAT pathway [64].
3.1.1. IL 28B polymorphisms and HCV1 infection
Several GWAS have demonstrated the role of SNPs near the interleukin 28B (IL 28B) gene in 
predicting PegIFN/RBV treatment outcome and spontaneous clearance of HCV infection [7, 
55]. Two bi-allelic SNPs were most strongly associated with favorable response in HCV geno-
type 1 (HCV-1) infected patients: rs8099917 located 8 kb downstream of the IL28B gene (favor-
able response TT genotype, and unfavorable GT/GG genotypes) and rs12979860 located 3 kb 
upstream of the IL28B gene (favorable response CC genotype, and unfavorable CT/TT geno-
types) [7]. Other SNPs of IL28B (rs8105790, rs11881222, rs28416813, rs4803219, and rs7248668) 
have been also identified in HCV genotype 1-infected patients, but they have not yet been 
strongly associated with the treatment outcome [55]. It has been shown that unfavorable IL28B 
genotypes expressed higher baseline ISGs levels compared with the favorable genotype, which 
could indicate an exhaustion of innate immunity prior to treatment in patients with unfavor-
able IL28B genotype [65–67]. In contrast, rs12979860 CC and rs8099917 TT genotypes were 
associated with low ISG expression at baseline, which led to greater ISG expression upon IFN 
treatment and better treatment responses [68]. Differences in the SVR rates were large and clin-
ically significant with a ~2-fold increase in SVR (70–80% vs. 40%) observed in patients carrying 
the favorable IL28B rs12979860 CC genotype [9]. Independent studies confirmed the associa-
tion of the IL28B genotype with SVR in various populations from Asia, Europe, and Latin 
America [9]. The IL28B favorable genotype also indicates an increased likelihood of achieving 
SVR among a pediatric population [69]. These treatment response findings were confirmed in 
different populations: HCV GT1 patients, HCV GT4 patients, patients with a recent HCV infec-
tion, adults and children with a spontaneous HCV clearance, HCV/HIV co-infected patients 
and patients with a recurrent HCV infection after orthotopic liver transplantation [7].
3.1.2. IL28B polymorphisms and HCV2/3 infection
Studies have shown different results which relate to association of IL28B SNP and HCV 2/3 
genotype infection. Mangia et al. showed that IL28B SNP rs12979860 was significantly associ-
ated with SVR to PEG-IFN/ribavirin therapy in chronic HCV genotype 2/3 [70]. Other studies 
demonstrated that the difference in the SVR rates between the IL28B genotypes was generally 
smaller in HCV-2/3 infections than in genotype 1 infection, which could indicate that IL28B 
has less value in predicting SVR in genotype 2 and 3 infections [9]. It is also possible that 
some studies did not achieve statistical significance because the SVR rates were generally high 
among patients infected with HCV-2/3 [9].
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3.1.3. IL28B polymorphisms and liver transplantation
HCV reinfection after liver transplantation can occur in most patients and had represented 
the primary reason for death and graft loss in the pre-DAA era [71]. The cause of the rein-
fection of the new liver is residual HCV, and IL28B genotype was shown to be an impor-
tant predictor of SVR for liver transplant recipients reinfected with HCV [9]. The rs12979860 
CC and rs8099917 TT genotypes of the recipient were notably associated with higher SVR 
rates, and the same trend was detected with the donor genotype [72]. Although, both donor 
and recipient IL28B genotypes have been associated with treatment response, it has not yet 
been confirmed which genotype is the better indicator of SVR, but it is clear that having both 
genotypes would be most informative [9]. Most of the study participants were infected with 
HCV-1, with scarce evidence for HCV non-genotype 1 infections [9]. Considering that this is a 
complicated patient population, other clinical factors should not be ignored while therapeutic 
decisions are made [9].
3.1.4. IL28B polymorphisms and HIV-HCV coinfection
Several studies have confirmed the association between IL28B genotypes and treatment 
response in HIV/HCV coinfected patients [9]. rs12979860 CC genotype and rs8099917 TT 
genotype have been demonstrated as strong predictors of SVR in HIV/HCV coinfection [9, 
68]. This association was observed in patients infected with genotype 1 and 4, but less obvi-
ous in patients with genotype 2 and 3 [9, 54, 68, 73]. SVR rates were generally higher among 
HCV-2 or 3-infected patients than those with HCV-1 or 4. Therefore, HCV2/3 genotype itself 
indicated good response to treatment [9]. Favorable rs12979860 CC genotype was associated 
with a higher SVR rate in a study of patients coinfected with HIV/HCV-1 or 4, even if patients 
were previous nonresponders to PegIFN/RBV therapy [73]. IL28B genotypes remained a good 
indicator of SVR, but they were not proven to affect HIV outcomes [73]. Consequently, IL28B 
genotypes should be interpreted only for the HCV outcomes, focusing on IFN-based treat-
ment of patients coinfected with HIV/HCV-1 or 4.
3.2. ITPA in prediction of adverse drug reactions
Hemolytic anemia is a very common side effect of RBV-based HCV therapy [9, 55]. In clini-
cal trials, 30% of treatment-naïve patients experienced anemia on PegIFN/RBV therapy, and 
most likely the major cause of anemia is ribavirin-induced hemolysis [68, 74]. Furthermore, 
in more than 15% of cases it is a cause of RBV dose reduction or premature discontinuation of 
RBV therapy, which may have had a deleterious impact on SVR [74, 75]. RBV depletes guano-
sine triphosphate (GTP) and causes a relative deficiency of ATP in human erythrocytes con-
sequently inhibiting the ATP-dependent oxidative metabolism [7]. Depletion of erythrocyte 
ATP content leads to oxidative damage to the erythrocyte membranes, consequently causing 
extravascular hemolysis by the reticuloendothelial system [76–78]. ITPA gene encodes ino-
sine-triphosphatase which is a protein that hydrolyses inosine triphosphate (ITP). A reduced 
ITPA activity advances the accumulation of ITP in erythrocytes allowing substitution of ITP 
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for GTP in ATP biosynthesis which reduces ATP depletion and protects against hemolytic 
anemia [79–82]. Two functional SNPs (rs1127354 and rs7270101) in the ITPA gene, respon-
sible for ITPA deficiency, were identified in two large GWAS [83, 84]. Consequently, the AA/
ACrs1127354 (for rs1127354, the wild-type and variant alleles are the C and A alleles) protective genotypes, as well as the CC/CArs7270101 (for rs7270101, the A allele is the wild type, and the C allele is the variant) protective genotypes, led to a decrease in hemolytic side effects from 
RBV therapy of HCV-1 infection [7]. Additionally, various studies showed an association 
between SNP ITPA and lower rates of clinically significant hemoglobin reduction among 
HIV/HCV coinfected patients [85–88]. Nevertheless, SNP ITPA does not predict SVR and 
was not associated to treatment outcomes [89]. However, considering that anemia is one of 
the main ADRs leading to premature withdrawal of therapy, any marker able to predict the 
risk of severe anemia before treatment would be of extreme importance [7]. For this purpose, 
two studies have designed predictions models incorporating ITPA genotype along with cre-
atinine clearance, baseline hemoglobin and quantitative hemoglobin decline at week 2 of 
treatment [90, 91]. Further validation before entering these algorithms into clinical practice 
is necessary [7].
4. HCV pharmacogenetic testing in the IFN-free era
Since pharmacogenomics played a very important role in the era of IFN-based therapy, 
questions arose as to whether pharmacogenomic markers would still have a meaning-
ful place in IFN-free treatment regimens involving DAA +/− ribavirin. Even though some 
studies suggested that HCV patients with the IL28B TT genotype had reduced therapeutic 
efficacy of some DAA regimens, IL28B genotyping did lose importance in the IFN-free era 
[15, 29, 92]. Furthermore, in African-American patients infected with HCV GT1a, ribavi-
rin is recommended to be added to ombitasvir plus paritaprevir/ritonavir or dasabuvir 
treatment regimens to improve cure rates [93]. Even though IL28B is not as important for 
IFN-free treatments as it was before, genotyping is still being routinely performed in some 
countries in order to identify patients likely to be cured with older drugs at significantly 
lower cost.
While new, effective, and well-tolerated drugs with fewer ADRs and minimal monitoring 
requirements are on the market, the high treatment price is reducing accessibility, leading 
to compromises in the price-effectiveness area. The high cost of IFN-free treatment regimens 
leads to a resource-guided therapy assessment in countries with a lower national afford-
ability for expensive DAAs [94]. The reason for further IL28B genotype determination in 
the era of available IFN-free treatments lies in the fact that patients with the interferon-
favorable CC allele combination achieve SVR in 70–80% when treated with PegIFN plus 
ribavirin, which makes this treatment regimen only a relatively acceptable alternative for 
those patients in countries with deficient resources for new and expensive treatments [9, 
94]. While in high-income countries like the USA as well as in most Northern and Western 
European countries, IFN-free treatments became first-line therapy for all patients with 
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chronic HCV infections, in lower- or middle-income countries, which represent around 85% 
of the HCV related global health burden. This is still inaccessible for socioeconomic reasons 
[95–97]. In resource-limited countries, treatment naïve patients with IL28B CC allele, a viral 
load below 400,000–800,000 IU/ml and a low stage liver fibrosis (F1 and F2), are considered 
as good responders to a 24-week IFN-based therapy with SVR rates up to 80%with PegIFN 
plus ribavirin treatment [94, 95, 97]. However, even though patients with IL28B non-CC 
allele or a higher viral load are not considered easy-to-cure, the initial therapy in Croatia is 
PegIFN plus ribavirin for patients suffering from low stage liver fibrosis (F1 or F2), with a 
treatment duration of 24–48 weeks if rapid virological response (RVR, defined as not detect-
able HCV RNA 4 weeks after treatment start) is achieved [98, 99]. In patients where RVR is 
not achieved, simeprevir or sofosbuvir are added to the treatment [98]. However, priority 
for obtaining IFN-free treatment for treatment naïve patients is accessed by evaluation of the 
liver fibrosis stage according to Metavir classification (whereas, F3 and F4 stages as well as 
decompensated liver cirrhosis, where contraindications for IFN-based regimens exist, are 
being prioritized for DAA treatments). Also, patients with greater risk for disease progres-
sion, with the existence of extrahepatic manifestations of the HCV infection, those who are 
at higher risk of viral transmission, with a presence of HIV-HCV coinfection or in the case of 
prior liver transplantation should be receive priority [98, 100]. However, for socioeconomic 
reasons, patients with liver fibrosis stages F1, F2, or F3 with relapse or only partial response 
to previous therapy are being treated with PegIFN plus ribavirin plus sofosbuvir/simeprevir 
in Croatia [98].
5. Conclusion
We have witnessed remarkable improvement in HCV therapy options, resulting from cutting-
edge discoveries. Treatment of HCV infection has been challenging since 1989, when HCV 
was first discovered and published [101]. After approval of interferon in 1992, great prog-
ress has been made. Consequently, many drugs have been introduced to clinical practice for 
HCV therapy [101]. In the late 2000s, another class of drugs, DAAs, was approved for use in 
combination therapy [101]. DAAs have been shown to be very effective HCV therapy, with 
high SVR rates and enhanced treatment safety. Nevertheless, barriers still remain in mak-
ing these therapies accessible worldwide. Drug pricing, screening and disease assessment, 
and public health prioritization represent the biggest issues associated with DAAs treatment 
accessibility [102, 103]. Development of pharmacogenetic testing in the IFN-ribavirin era has 
been remarkable, leading to the discovery of various genetic polymorphisms associated with 
treatment outcome predictions. Although application of pharmacogenetic testing in IFN-free 
DAA era has been doubtful, it could play an important role in concept of “resource-guided 
therapy,” where peginterferon/ribavirin might be applied for easy-to-treat interferon-eligible 
patients in resource-constrained areas [94]. Although treatment efficacy of HCV infection has 
increased dramatically, the goal of making the therapy available to everyone in need remains 
a major challenge.
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